Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment
about
De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shockDe-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shockQ24240274Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortalityEvaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratificationBench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysisDirect identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry.Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.The Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the EvidenceA functionalized surface modification with vanadium nanoparticles of various valences against implant-associated bloodstream infectionTiming of antimicrobial therapy after identification of ventilator-associated condition is not associated with mortality in patients with ventilator-associated pneumonia: a cohort study.Imipenem resistance of Pseudomonas in pneumonia: a systematic literature reviewPseudomonas aeruginosa urinary tract infections in hospitalized patients: Mortality and prognostic factors.Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysisAntimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort studyGram-negative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes.Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.The multiple signaling systems regulating virulence in Pseudomonas aeruginosa.Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.Rapid detection of Pseudomonas aeruginosa from positive blood cultures by quantitative PCR.Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with gram-negative sepsisExtensively drug-resistant pseudomonas aeruginosa isolates containing blaVIM-2 and elements of Salmonella genomic island 2: a new genetic resistance determinant in Northeast OhioQuorum quenching enzyme activity is widely conserved in the sera of mammalian species.Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents.Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomesPseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae.Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes.Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.Microbiological profiling and the demonstration of in vitro anti-bacterial traits of the major oral herbal medicines used in Dhaka Metropolis.Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay.Performance of Kiestra total laboratory automation combined with MS in clinical microbiology practiceHigh-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis.Glyphosate, pathways to modern diseases III: Manganese, neurological diseases, and associated pathologies.Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study.Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
P2860
Q24198268-6409608A-77F7-408A-BA74-B0168D4B7585Q24235566-3B447CFA-1035-453E-82D4-A15D99B88D16Q24240274-5315D02B-75AF-4A7D-B13E-F4DA225E9579Q24530412-185E6FFA-D5B4-40FA-B3FE-09DBA2FD3E41Q24615937-F6C4F548-A3A9-4E39-B74B-9FC104D800EDQ24813204-359B6188-36B4-4438-8334-CFA5B5541FDFQ26783911-4490E8E2-2240-40BE-B817-3CB177E3C841Q30927749-8976F5E4-BDA3-4CF6-AAFF-4504A57AC3DDQ31004673-E9302D8D-9C12-46D8-B0BE-C19D0B380E41Q33236778-85023F9A-26A1-45AD-9759-E0CA5E665FEBQ33564316-7A9F6CEB-C872-4514-B30B-A0F99C223973Q33596392-9D3E0CB6-99C9-4116-B84B-0AD8D40AEE5CQ33632826-FE8C9CA5-162B-4328-9439-5686F89CF154Q33675546-19747267-211C-415E-982E-226D61E11361Q33732032-158241A8-832C-498C-A4F8-F925E060503AQ33826400-30642E6F-A71D-4966-AE68-6C0FCE9DA89AQ33867208-7D5074A9-168F-465D-B36C-B5425BFFC3A9Q33988563-D8D4D331-C18E-4B36-8EFD-462104EEC4CEQ34003193-605C0A73-8374-4CF8-AC19-8B65354B07BBQ34030980-741241D8-C90A-4053-BB8A-029344F4CC05Q34064473-1761269F-D6C6-446A-8083-14E670797532Q34086132-240E63EF-2468-4BE1-AFE8-130A381A8566Q34108708-5634EFE6-1FF9-44E2-945F-D6607E852E71Q34194422-48F3A6A1-5B2D-4CE2-8EBF-B500943C85B1Q34298956-1F42BABE-63FE-42F8-97C4-1B94CAF7A5A2Q34427327-34E06D23-772B-4E84-9295-728CE6D3A43FQ34431957-BBE34BFD-0AD3-4A3B-853B-87DAE27D2637Q34446914-49C1B708-5597-4817-87D8-3EDDEAB22F12Q34766191-3C8DCB6B-9D27-49EF-B13A-99BC3D7FA9E6Q34839432-65E9C31C-CF59-41BB-87E4-063493CA6923Q34853371-22103940-A731-41D4-A8A6-A204A4EF5C1DQ35007624-008C5438-1421-4633-956D-E144DBDF75BEQ35059110-DB021FAA-04E7-408E-9EF7-AB86BCF57A35Q35091494-2CC2BDA2-D09C-4703-AB32-E655F8FE32B1Q35119444-3B6E8DBA-23D7-4ED5-8EA4-69518D57F063Q35141040-E1AFBB29-5B07-47E8-9709-61A77B0AD728Q35174295-07A8AE6F-A4B8-4C02-B21C-01AD8C699273Q35355392-CCE611CF-1C1C-48B6-B97E-2525FB1C2EB4Q35544667-5C6A67A8-52C7-4652-8EFB-D05AF6835943Q35545954-F58BE500-8BDA-4B03-AC52-88739937DFA4
P2860
Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pseudomonas aeruginosa bloodst ...... nitial antimicrobial treatment
@ast
Pseudomonas aeruginosa bloodst ...... nitial antimicrobial treatment
@en
type
label
Pseudomonas aeruginosa bloodst ...... nitial antimicrobial treatment
@ast
Pseudomonas aeruginosa bloodst ...... nitial antimicrobial treatment
@en
prefLabel
Pseudomonas aeruginosa bloodst ...... nitial antimicrobial treatment
@ast
Pseudomonas aeruginosa bloodst ...... nitial antimicrobial treatment
@en
P2093
P2860
P1476
Pseudomonas aeruginosa bloodst ...... nitial antimicrobial treatment
@en
P2093
Ann E Lloyd
David J Ritchie
Richard M Reichley
Scott T Micek
Victoria J Fraser
P2860
P304
P356
10.1128/AAC.49.4.1306-1311.2005
P407
P577
2005-04-01T00:00:00Z